

Non Hormonal Contraceptives Market for Women's Health by Target Indication (Bacterial Vaginosis, Contraception, Endometriosis, Postmenopausal Osteoporosis, Uterine Fibroids, Vaginitis and Others), Type of Molecule (Biologic and Small Molecule), Purpose of Therapy (Treatment of Disease and Management of Symptoms), Mechanism of Action (Antagonist, Agonist, Inhibitor and Modulator), Route of Administration (intramuscular, intravaginal, intravenous, oral, subcutaneous, topical, transdermal and others), and Key Geographical Regions (North America, Europe and Asia-Pacific): Industry Trends and Global Forecasts, 2021-2030

<https://marketpublishers.com/r/NFAC0EA42EB5EN.html>

Date: March 2021

Pages: 225

Price: US\$ 4,799.00 (Single User License)

ID: NFAC0EA42EB5EN

Abstracts

The non hormonal contraceptives market is expected to reach USD 1.8 billion in 2021 and anticipated to grow at a CAGR of 22% during the forecast period 2021-2030.

According to the World Health Organization (WHO), around one-third of clinical conditions prevalent among females aged 15 to 44 are linked to sexual and reproductive health. The complex female reproductive system operates under the influence of estrogen and progesterone. Imbalances in these hormones can lead to various ailments, mood disturbances, and unexplained physical symptoms, more prevalent in females than males. Since the 1960s, interventions regulating hormones have been developed and used, gaining widespread acceptance after demonstrating

effectiveness in late 1990s clinical trials. However, subsequent studies have uncovered a correlation between these interventions and unwanted side effects, such as an elevated risk of hormone-dependent cancers.

Recent strides in non-hormonal contraceptives have revolutionized women's healthcare. Brisdelle®, approved in 2013 for managing menopausal hot flashes, signaled the advent of such non-hormonal contraceptives. Currently, 21 non-hormonal contraceptives (e.g., Oriahnn™, Phexxi™, and Esmya®) have obtained approval. Furthermore, several non-hormonal birth control options are undergoing evaluation at various developmental stages. Clinical trials and post-approval studies have underscored the inherent advantages of non-hormonal birth control, including a superior safety profile, preservation of hormonal equilibrium, and shorter treatment durations compared to hormonal therapies. Consequently, non-hormonal contraceptives are now preferred over hormone-based treatments, and the pipeline for non-hormonal birth control is expected to steadily expand.

This market has witnessed substantial collaboration among stakeholders to strategically support ongoing product development and commercialization endeavors. The promising outcomes anticipated from ongoing clinical research are likely to attract more investments, driving the development of products in this burgeoning market segment. Consequently, substantial market growth is expected in this domain during the forecast period.

Report Coverage

The report conducts an analysis of the non-hormonal contraceptive market, focusing on target indications, molecule types, therapeutic purposes, therapy mechanisms, administration routes, and key geographical regions.

It examines factors such as drivers, restraints, opportunities, and challenges influencing market growth.

Assessment of potential advantages and hurdles within the market is provided, along with insights into the competitive landscape for leading market players.

Revenue forecasts for market segments are presented concerning three major regions.

A comprehensive exploration of the current market landscape for non-hormonal

therapies, including their developmental phases, molecular classifications, target indications, therapeutic objectives, target populations, mechanisms of action, routes of administration, and any special drug designations received.

Detailed profiling of entities involved in developing non-hormonal therapies, outlining establishment years, company sizes, headquarters locations, and regional presence.

In-depth discussion of diverse commercialization strategies applicable to drug developers in the non-hormonal contraceptives market, tailored to different stages of therapy development from pre-launch to post-marketing phases.

Detailed profiles of phase III non-hormonal therapies, encompassing concise overviews, developmental status, administration routes, primary indications, dosages, mechanisms of action, clinical trials, trial outcomes, collaborations, and special drug designations.

Meticulous analysis of geographical clinical trials, covering completed and ongoing studies of non-hormonal therapies, considering parameters such as trial registration year, status, phase, indications, geographic locations, sponsor types, treatment sites, and enrolled patient populations.

Evaluation of partnerships established by stakeholders involved in non-hormonal therapy development from pre-2013 to 2020, inclusive of research agreements, R&D partnerships, manufacturing contracts, licensing deals, and other collaborations. Additionally, a detailed examination of investments made, including awards/grants, financing sources like venture capital, debt financing, and other financial contributions in companies engaged in the non-hormonal birth control market.

Key Market Companies

AbbVie

Adjuvant Capital

Amgen

Astellas Pharma

Bayer

Boehringer Ingelheim

Cidara Therapeutics

Eli Lilly

Contents

1. PREFACE

- 1.1. Scope of the Report
- 1.2. Research Methodology
- 1.3. Key Questions Answered
- 1.4. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION

- 3.1. Chapter Overview
- 3.2. Women's Health and Affiliated Clinical Conditions
 - 3.2.1. Key Milestones in the Treatment of Women's Health-related Disorders
- 3.3. Women's Health-related Conditions
- 3.4. Available Treatment Modalities
 - 3.4.1. Surgery
 - 3.4.2. Hormonal Therapies
 - 3.4.3. Non-Hormonal Therapies
- 3.5. Future Perspectives

4. MARKET OVERVIEW

- 4.1. Chapter Overview
- 4.2. Non-hormonal Therapies Market: Pipeline
 - 4.2.1. Analysis by Phase of Development
 - 4.2.2. Analysis by Type of Molecule
 - 4.2.3. Analysis by Target Indication
 - 4.2.4. Analysis by Phase of Development and Target Indication
 - 4.2.5. Analysis by Type of Molecule and Target Indication
 - 4.2.6. Analysis by Purpose of Therapy
 - 4.2.7. Analysis by Target Women Population
 - 4.2.8. Analysis by Mechanism of Action
 - 4.2.9. Analysis by Route of Administration
 - 4.3.1. Analysis by Special Designation(s) Awarded

5. COMPETITIVE LANDSCAPE

- 5.1. Chapter Overview
- 5.2. Non-hormonal Therapies Market: List of Developers
 - 5.2.1. Analysis by Year of Establishment
 - 5.2.2. Analysis by Company Size
 - 5.2.3. Analysis by Geography
- 5.3. Key Players: Analysis by Number of Product Candidates
- 5.4. Big Pharma Initiatives

6. KEY COMMERCIALIZATION STRATEGIES

- 6.1. Chapter Overview
- 6.2. Successful Drug Launch Strategy: ROOTS Framework
- 6.3. Successful Drug Launch Strategy: Product Differentiation
- 6.4. Commonly Adopted Commercialization Strategies based on the Development Stage of the Product
- 6.5. Approved Non-hormonal Prescription Drugs
- 6.6. Key Commercialization Strategies Adopted by Companies Focused on Women's Health
 - 6.6.1. Strategies Adopted Before Therapy Approval
 - 6.6.1.1. Participation in Global Events
 - 6.6.1.2. Collaboration with Industry Stakeholders and Other Pharmaceutical Firms
 - 6.6.1.3. Expansion of Target Indication
 - 6.6.2. Strategies Adopted During / Post Therapy Approval
 - 6.6.2.1. Geographical Expansion
 - 6.6.2.2. Participation in Global Events
 - 6.6.2.3. Patient Assistance Programs
 - 6.6.2.4. Awareness Through Product Websites
 - 6.6.2.5. Collaboration with Industry Stakeholders and Other Pharmaceutical Firms
 - 6.6.2.6. Aligning with Government Initiatives to Ensure High Adoption Rate
- 6.7. Concluding Remarks

7. DRUG PROFILES (PHASE III)

- 7.1. Chapter Overview
- 7.2. Relugolix
- 7.3. DARE-BV1 (Clindamycin gel)
- 7.4. Ovaprene®
- 7.5. Yselty® (Linzagolix)

- 7.6. Fezolinetant
- 7.7. BAY1002670 (Vilaprisan)
- 7.8. Abaloparatide-TD
- 7.9. Terconazole (0.4%)
- 7.10. SCY-078 (Ibrexafungerp)
- 7.11. VT-1161 (Oteseconazole)
- 7.12. MV140 (Uromune)
- 7.13. Orilissa™ (Elagolix)
- 7.14. EVO100 (Amphora)

8. CLINICAL TRIAL ANALYSIS

- 8.1. Chapter Overview
- 8.2. Scope and Methodology
- 8.3. Non-hormonal Therapies: Clinical Trial Analysis
 - 8.3.1. Analysis by Trial Registration Year
 - 8.3.2. Analysis by Trial Status
 - 8.3.3. Analysis by Trial Phase
 - 8.3.4. Analysis by Trial Registration Year and Trial Status
 - 8.3.5. Analysis by Target Patient Segment
 - 8.3.6. Analysis by Target Indication
 - 8.3.7. Analysis by Type of Sponsor
 - 8.3.8. Analysis by Geography
 - 8.3.8.1. Analysis by Geography (Pre-2017 and Post 2017)
- 8.4. Non-Hormonal Therapies: Analysis by Enrolled Patient Population
 - 8.4.1. Analysis by Trial Registration Year
 - 8.4.2. Analysis by Trial Status
 - 8.4.3. Analysis by Trial Phase
 - 8.4.4. Analysis by Geography
 - 8.4.4.1. Analysis by Geography (Pre-2017 and Post 2017)
- 8.5. Analysis by Study Design
- 8.6. Concluding Remarks
 - 8.6.1. Emerging Molecules to Watch
 - 8.6.2. Most Important Trials to Watch

9. RECENT DEVELOPMENTS

- 9.1. Chapter Overview
- 9.2. Partnership Models

9.3. Non-hormonal Therapies: Recent Partnerships

9.3.1. Analysis by Year of Partnership

9.3.2. Analysis by Type of Partnership

9.3.3. Analysis by Target Indication

9.3.4. Most Active Players: Analysis by Number of Partnerships

9.3.5. Geographical Analysis

9.3.5.1. Intercontinental and Intracontinental Agreements

9.4. Types of Funding

9.5. Non-Hormonal Therapies: Funding and Investment Analysis

9.5.1. Analysis by Number of Funding Instances

9.5.2. Analysis by Amount Invested

9.5.3. Analysis by Type of Funding

9.5.4. Analysis by Type of Funding and Year

9.5.5. Analysis by Funding Amount and Year

9.5.6. Regional Analysis by Amount Invested

9.5.7. Most Active Players

9.6. Concluding Remarks

10. MARKET FORECAST AND OPPORTUNITY ANALYSIS

10.1. Chapter Overview

10.2. Scope and Limitations

10.3. Key Assumptions and Forecast Methodology

10.4. Global Non-hormonal Therapies for Women's Health Market, 2021-2030

10.4.1. Non-hormonal Therapies Market: Analysis by Target Indication

10.4.2. Non-hormonal Therapies Market: Analysis by Type of Molecule

10.4.3. Non-hormonal Therapies Market: Analysis by Route of Administration

10.4.4. Non-hormonal Therapies Market: Analysis by Geography

10.5. Non-hormonal Therapies for Women's Health Market: Value Creation Analysis

10.5.1. Bacterial Vaginosis

10.5.2. Contraception

10.5.3. Endometriosis

10.5.4. Postmenopausal Osteoporosis

10.5.5. Uterine Fibroids

10.5.6. Vasomotor Symptoms

10.6. Non-hormonal Therapies for Women's Health Market: Product Wise Sales

Forecasts

10.6.1. Nuvessa (Metronidazole)

10.6.1.1. Target Patient Population

- 10.6.1.2. Sales Forecast
- 10.6.1.3. Net Present Value
- 10.6.2. VivaGel (SPL 7013)
 - 10.6.2.1. Target Patient Population
 - 10.6.2.2. Sales Forecast
 - 10.6.2.3. Net Present Value
- 10.6.3. Solosec (Secnidazole)
 - 10.6.3.1. Target Patient Population
 - 10.6.3.2. Sales Forecast
 - 10.6.3.3. Net Present Value
- 10.6.4. Tymlos (Abaloparatide)
 - 10.6.4.1. Target Patient Population
 - 10.6.4.2. Sales Forecast
 - 10.6.4.3. Net Present Value
- 10.6.5. Orilissa
 - 10.6.5.1. Target Patient Population
 - 10.6.5.2. Sales Forecast (Endometriosis)
 - 10.6.5.3. Sales Forecast (Uterine Fibroids)
 - 10.6.5.4. Net Present Value
- 10.6.6. Ospheña (Ospemifene)
 - 10.6.6.1. Target Patient Population
 - 10.6.6.2. Sales Forecast
 - 10.6.6.3. Net Present Value
- 10.6.7. Evenity(Romozosumab-aqqg)
 - 10.6.7.1. Target Patient Population
 - 10.6.7.2. Sales Forecast
 - 10.6.7.3. Net Present Value
- 10.6.8. Esmya and Fibrystal (Ulipristal acetate)
 - 10.6.8.1. Target Patient Population
 - 10.6.8.2. Sales Forecast
 - 10.6.8.3. Net Present Value
- 10.6.9. Phexxi (Amphora)
 - 10.6.9.1. Target Patient Population
 - 10.6.9.2. Sales Forecast
 - 10.6.9.3. Net Present Value
- 10.6.10. Oriahnn
 - 10.6.10.1. Target Patient Population
 - 10.6.10.2. Sales Forecast
 - 10.6.10.3. Net Present Value

- 10.6.11. Relugolix
 - 10.6.11.1. Target Patient Population
 - 10.6.11.2. Sales Forecast (Uterine Fibroids)
 - 10.6.11.3. Sales Forecast (Endometriosis)
 - 10.6.11.4. Net Present Value
- 10.6.12. DARE-BV1 (Clindamycin gel)
 - 10.6.12.1. Target Patient Population
 - 10.6.12.2. Sales Forecast
 - 10.6.12.3. Net Present Value
- 10.6.13. Ovaprene
 - 10.6.13.1. Target Patient Population
 - 10.6.13.2. Sales Forecast
 - 10.6.13.3. Net Present Value
- 10.6.14. Yselty (Linzagolix)
 - 10.6.14.1. Target Patient Population
 - 10.6.14.2. Sales Forecast (Endometriosis)
 - 10.6.14.3. Sales Forecast (Uterine Fibroids)
 - 10.6.14.3. Net Present Value
- 10.6.15. Fezolinetant
 - 10.6.15.1. Target Patient Population
 - 10.6.15.2. Sales Forecast
 - 10.6.15.3. Net Present Value
- 10.6.16. BAY1002670 (Vilaprisan)
 - 10.6.16.1. Target Patient Population
 - 10.6.16.2. Sales Forecast
 - 10.6.16.3. Net Present Value
- 10.6.17. Abaloparatide-TD
 - 10.6.17.1. Target Patient Population
 - 10.6.17.2. Sales Forecast
 - 10.6.17.3. Net Present Value
- 10.6.18. Terconazole(0.4%)
 - 10.6.18.1. Target Patient Population
 - 10.6.18.2. Sales Forecast
 - 10.6.18.3. Net Present Value
- 10.6.19. SCY-078 (Ibexafungerp)
 - 10.6.19.1. Target Patient Population
 - 10.6.19.2. Sales Forecast
 - 10.6.19.3. Net Present Value
- 10.6.20. VT-1161 (Oteseconazole)

- 10.6.20.1. Target Patient Population
- 10.6.20.2. Sales Forecast
- 10.6.20.3. Net Present Value
- 10.6.21. MV140 (Uromune)
 - 10.6.21.1. Target Patient Population
 - 10.6.21.2. Sales Forecast
 - 10.6.21.3. Net Present Value
- 10.6.22. EVO100
 - 10.6.22.1. Target Patient Population
 - 10.6.22.2. Sales Forecast
 - 10.6.22.3. Net Present Value

11. CONCLUDING REMARKS

12. APPENDIX 1: TABULATED DATA

13. APPENDIX 2: LIST OF COMPANIES

I would like to order

Product name: Non Hormonal Contraceptives Market for Women's Health by Target Indication (Bacterial Vaginosis, Contraception, Endometriosis, Postmenopausal Osteoporosis, Uterine Fibroids, Vaginitis and Others), Type of Molecule (Biologic and Small Molecule), Purpose of Therapy (Treatment of Disease and Management of Symptoms), Mechanism of Action (Antagonist, Agonist, Inhibitor and Modulator), Route of Administration (intramuscular, intravaginal, intravenous, oral, subcutaneous, topical, transdermal and others), and Key Geographical Regions (North America, Europe and Asia-Pacific): Industry Trends and Global Forecasts, 2021-2030

Product link: <https://marketpublishers.com/r/NFAC0EA42EB5EN.html>

Price: US\$ 4,799.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/NFAC0EA42EB5EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970